furosemide has been researched along with rivastigmine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
| Benek, O; Benkova, M; Dolezal, R; Hepnarova, V; Hrabinova, M; Janockova, J; Jun, D; Kobrlova, T; Korabecny, J; Kucera, T; Mezeiova, E; Prchal, L; Sobolova, K; Soukup, O | 1 |
| Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M | 1 |
1 review(s) available for furosemide and rivastigmine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for furosemide and rivastigmine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |
Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
Topics: Berberine; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Prolyl Oligopeptidases | 2020 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |